Nyon, Switzerland and Potsdam, Germany, October 25, 2016 – Elanix Biotechnologies AG (“Elanix” – FSE: ELN), a developer of tissue regeneration and cosmetic products announced today that Elanix Sàrl in Switzerland (a fully-owned subsidiary of Elanix Biotechnologies AG, Potsdam) under the terms of the worldwide exclusive licensing agreement with the Lausanne University Hospital , Switzerland (CHUV) has been awarded the United States Patent No. 9434923 B2 entitled “Preparation of parental Cell Bank from Foetal Tissue”.

The patented invention relates to methods of producing large amounts of skin fibroblast, tenocytes, and chondrocytes progenitor cells (Parental Cell Banks, PCBs) in vitro and their use to repair, treat, and regenerate diseased or wounded tissues such as, osteochondral, musculoskeletal, tendon, cartilage and skin tissues. The invention also covers for the use of those cells as an in vitro platform to screen for safety and efficacy of therapeutic agents developed for treating arthritic, osteochondral defects or musculoskeletal, tendon, cartilage and skin injury. The organs and tissues at the origin of the cell banks have been obtained in full compliance with Swiss laws and guidelines on, organ/tissue donation. Cell banks are created in specialized facilities certified for current Good Manufacturing Practice (cGMP).

“Skin fibroblasts, tendon and cartilage progenitors display unique safety and efficacy properties as demonstrated in numerous peer-reviewed scientific and clinical publications. This patent award consolidates Elanix in its growing patent portfolio and strengthens Elanix position in protecting, validating and industrializing its cutting-edge technology for commercialization.” Says Riccardo Nisato, Ph.D., MBA, General Manager Tissue Engineering Products Business Unit and Head of QA&RA.

“We are pleased to have the uniqueness and innovativeness of Elanix technology platform approved by a renowned third party – US patent office. We are already working on further expansion of our IP portfolio”, says Tomas J. Svoboda, BSc., MBA, CEO of Elanix Biotechnologies AG

Elanix Biotechnologies (Frankfurt: ELN) develops and commercializes tissue regeneration products for acute wound care, dermatological and gynecological applications, and provides services in cell technologies. Cosmetic-based products derive from animal tissue sources while tissue regeneration products for medical use derive from human tissues. Elanix complies with appropriate legislations on cosmetics and medical applications in Switzerland and worldwide. The company was founded in 2013 as a spin-out from the Lausanne University Hospital (CHUV), Switzerland, to develop and commercialize medicinal products based on a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks with vast quantities of cells of different cell types.

The Company is headquartered in Nyon, Switzerland with offices in Potsdam and listed on the Frankfurt stock exchange under the symbol ELN. For more information and updates, visit www.elanix-biotechnologies.com.

Press Contact:
Maria Widowski
Elanix Biotechnologies AG
Phone number 0049 331 583 945 10

Disclaimer / Forward-looking statements:

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Elanix Biotechnologies AG. This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the “United States”), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

This publication may contain certain forward-looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.